Personalized medicine: Changing the paradigm of drug development

Methods in Molecular Biology

Volumn 823, Issue , 2012, Pages 367-378

  Couch, Robin D ^a   Mott, Bryan T ^b  

^a GEORGE MASON UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Clinical trials; Drug development; High throughput screening; Personalized medicine; Theranostic

Indexed keywords

ARTICLE; DRUG DEVELOPMENT; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS;

DRUG DISCOVERY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 82355182990     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60327-216-2_24     Document Type: Article

References (53)

1. Hillisch, A., and Hilgenfeld, R. (2003) Modern methods of drug discovery . Birkhauser Verlag, Basel, Switzerland.
2. Fleischmann, R. D., Adams, M. D., White, O., Clayton, R. A., Kirkness, E. F. , et al. (1995) Whole-genome random sequencing and assembly of Haemophilus infiuenzae Rd. Science 269, 496-512.
3. Jawaid, S., Seidle, H., Zhou, W., Abdirahman, H., Abadeer, M. , et al. (2009) Kinetic characterization and phosphoregulation of the Francisella tularensis 1-deoxy-D-xylulose 5-phosphate reductoisomerase (MEP synthase). PLoS One 4, e8288.
4. Drews, J. (2000) Drug discovery: a historical perspective. Science 287, 1960-4. (Pubitemid 30158662)
5. Abuin, A., Holt, K. H., Platt, K. A., Sands, A. T., and Zambrowicz, B. P. (2002) Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol 20, 36-42. (Pubitemid 34015907)
6. Tornell, J., and Snaith, M. (2002) Transgenic systems in drug discovery: from target identification to humanized mice. Drug Discov Today 7, 461-70. (Pubitemid 34537259)
7. Sanseau, P. (2001) Transgenic gene knockouts: a functional platform for the industry. Drug Discov Today 6, 770-71. (Pubitemid 32722217)
8. Tse, E., Lobato, M. N., Forster, A., Tanaka, T., Chung, G. T. , et al. (2002) Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J Mol Biol 317, 85-94. (Pubitemid 34722201)
9. Ivy, S. P., Wick, J. Y., and Kaufman, B. M. (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol .
10. Bartz, S., and Jackson, A. L. (2005) How will RNAi facilitate drug development? Sci STKE 2005, pe39.
11. Zaffaroni, N., Pennati, M., and Folini, M. (2007) Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs. Methods Mol Biol 361, 239-63. (Pubitemid 350183211)
12. Davies, J. W., Glick, M., and Jenkins, J. L. (2006) Streamlining lead discovery by aligning in silico and high-throughput screening. Curr Opin Chem Biol 10, 343-51. (Pubitemid 44080652)
13. Bender, A., Bojanic, D., Davies, J. W., Crisman, T. J., Mikhailov, D. , et al. (2008) Which aspects of HTS are empirically correlated with downstream success? Curr Opin Drug Discov Devel 11, 327-37. (Pubitemid 351572442)
14. Lam, K. S. (2007) New aspects of natural products in drug discovery. Trends Microbiol 15, 279-89. (Pubitemid 46856162)
15. Musonda, C. C., and Chibale, K. (2004) Application of combinatorial and parallel synthesis chemistry methodologies to antiparasitic drug discovery. Curr Med Chem 11, 2519-33. (Pubitemid 39255548)
16. Glickman, J. F., Schmid, A., and Ferrand, S. (2008) Scintillation proximity assays in highthroughput screening. Assay Drug Dev Technol 6, 433-55.
17. Liu, B., Li, S., and Hu, J. (2004) Technological advances in high-throughput screening. Am J Pharmacogenomics 4, 263-76. (Pubitemid 39145474)
18. Thomas, G. (2007) Medicinal chemistry: an introduction . John Wiley and Sons, Hoboken, NJ.
19. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46, 3-26. (Pubitemid 33653411)
20. Barton, P., Davis, A. M., McCarthy, D. J., and Webborn, P. J. (1997) Drug-phospholipid interactions. 2. Predicting the sites of drug distribution using n-octanol/water and membrane/water distribution coefficients. J Pharm Sci 86, 1034-9. (Pubitemid 27382906)
21. Artursson, P., Palm, K., and Luthman, K. (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46, 27-43.
22. Bachmann, K. A., and Ghosh, R. (2001) The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr Drug Metab 2, 299-314. (Pubitemid 32782798)
23. Gres, M. C., Julian, B., Bourrie, M., Meunier, V., Roques, C. , et al. (1998) Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm Res 15, 726-33. (Pubitemid 28275649)
24. Irvine, J. D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J. W. , et al. (1999) MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 88, 28-33. (Pubitemid 29037364)
25. Mott, B. T., Ferreira, R. S., Simeonov, A., Jadhav, A., Ang, K. K. , et al. (2010) Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB. J Med Chem 53, 52-60.
26. Ferreira, R. S., Simeonov, A., Jadhav, A., Eidam, O., Mott, B. T. , et al. (2010) Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem 53, 4891-905.
27. Miller, S. C., Huang, R., Sakamuru, S., Shukla, S. J., Attene-Ramos, M. S. , etal. (2010) Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol 79, 1272-80.
28. Mott, B. T., Tanega, C., Shen, M., Maloney, D. J., Shinn, P. , et al. (2009) Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). Bioorg Med Chem Lett 19, 6700-5.
29. Marinello, J., Marchand, C., Mott, B. T., Bain, A., Thomas, C. J. , et al. (2008) Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 47, 9345-54.
30. Neumann, S., Huang, W., Eliseeva, E., Titus, S., Thomas, C. J. , et al. (2010) A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. Endocrinology 151, 3454-9.
31. Thorne, N., Auld, D. S., and Inglese, J. (2010) Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr Opin Chem Biol 14, 315-24.
32. Jadhav, A., Ferreira, R. S., Klumpp, C., Mott, B. T., Austin, C. P. , et al. (2010) Quantitative analyses of aggregation, autofiuorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem 53, 37-51.
33. Simeonov, A., Jadhav, A., Thomas, C. J., Wang, Y., Huang, R. , et al. (2008) Fluorescence spectroscopic profiling of compound libraries. J Med Chem 51, 2363-71. (Pubitemid 351628498)
34. Frantz, S. (2004) FDA publishes analysis of the pipeline problem. 3, 379.
35. Gilbert, J., Henske, P., and Singh, A. (2003) Rebuilding big pharma's business model. In Vivo The Business & Medicine Report 21, 1-4.
36. Dimasi, J. A. (2001) Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 69, 297-307.
37. Bouchie, A. (2006) Clinical trial data: to disclose or not to disclose? Nat Biotechnol 24, 1058-60. (Pubitemid 44359703)
38. Bange, J., Zwick, E., and Ullrich, A. (2001) Molecular targets for breast cancer therapy and prevention. Nat Med 7, 548-52. (Pubitemid 32448320)
39. Nahta, R., and Esteva, F. J. (2003) HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 9, 5078-84. (Pubitemid 37413555)
40. Seidman, A., Hudis, C., Pierri, M. K., Shak, S., Paton, V. , et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20, 1215-21. (Pubitemid 34177427)
41. Marko-Varga, G., Ogiwara, A., Nishimura, T., Kawamura, T., Fujii, K. , et al. (2007) Personalized medicine and proteomics: lessons from non-small cell lung cancer. J Proteome Res 6, 2925-35. (Pubitemid 47315558)
42. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H. , et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-500. (Pubitemid 38720929)
43. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K. , et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101, 13306-11. (Pubitemid 39209661)
44. Kim, K. S., Jeong, J. Y., Kim, Y. C., Na, K. J., Kim, Y. H. , et al. (2005) Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11, 2244-51.
45. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A. , et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-39. (Pubitemid 38637993)
46. Hetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O. , et al. (2001) Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 23, 1603-14. (Pubitemid 33063588)
47. Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M. , et al. (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-32. (Pubitemid 34215071)
48. Zucman, D., Truchis, P., Majerholc, C., Stegman, S., and Caillat-Zucman, S. (2007) Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 45, 1-3. (Pubitemid 46684436)
49. Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C. , et al. (2006) Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 43, 99-102. (Pubitemid 43939082)
50. Bender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K. , et al. (2007) Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2, 861-73.
51. Crisman, T. J., Parker, C. N., Jenkins, J. L., Scheiber, J., Thoma, M. , et al. (2007) Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data. J Chem Inf Model 47, 1319-27. (Pubitemid 47210036)
52. Scheiber, J., Jenkins, J. L., Sukuru, S. C., Bender, A., Mikhailov, D. , et al. (2009) Mapping adverse drug reactions in chemical space. J Med Chem 52, 3103-7.
53. Scheiber, J., Chen, B., Milik, M., Sukuru, S. C., Bender, A. , et al. (2009) Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis. J Chem Inf Model 49, 308-17.